Longitudinal circulating tumor DNA monitoring in predicting response to short-course neoadjuvant radiotherapy in locally advanced rectal cancer: Data from a phase III clinical trial (UNION).

Authors

Zhenyu Lin

Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Zhenyu Lin , Menglan Zhai , Linghua Yan , Tao Zhang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O⁶-methylguanine DNA methyltransferase) status: KCSG-CO17-02.

First Author: Chung Ryul Oh

insert_chart_outlined

Poster

2019 Gastrointestinal Cancers Symposium

bookmark_border

Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).

First Author: Susan G.R. McDuff

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

The potential of circulating tumor DNA (ctDNA) to guide adjuvant chemotherapy decision making in locally advanced rectal cancer (LARC).

First Author: Jeanne Tie

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

Phase I study of preoperative chemoradiation with temozolomide and capecitabine in patients with locally advanced rectal cancer.

First Author: Yong Sang Hong